Association of pyrazinamide resistance in Mycobacterium tuberculosis with mutations in rpoB, katG, and inhA genes.

Kartiki Srivastava, Salman Khan, Rajniti Prasad, Sada Nand Pandey, Shampa Anupurba

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kartiki SrivastavaDepartment of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India.

Salman KhanDepartment of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India.

Rajniti PrasadDepartment of Pediatrics, Sir Sunderlal Hospital, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India.

Sada Nand PandeyDepartment of Zoology, Institute of Science, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India.

Shampa AnupurbaDepartment of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India. shampa@bhu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is associated with a high rate of treatment failure. Since the 9 to 11-month shorter oral regimen in MDR-TB treatment includes pyrazinamide (PZA), it is essential to assess the susceptibility of MDR-TB strains to PZA to guide effective therapy. The susceptibility of PZA is highly affected by drug pressure induced by rifampicin (RIF) and isoniazid (INH) resistant strains. This study examines the association between point mutations in the rpoB, katG, inhA, and pncA genes. Resistant patterns of MDR strains were detected through line probe assay. Phenotypic drug susceptibility testing for PZA was performed using MGIT 960 liquid culture for RIF-resistant, INH-resistant, and multidrug-resistant strains. In addition, pncA gene was sequenced to characterize the associated mutation pattern. Out of 780 MTB-positive strains, 195 were found to be resistant to first-line drugs (RIF and/or INH). Among those 195 resistant isolates, 107 (54.87%) were resistant, and 88 (45.12%) were susceptible to PZA. Mutations at S531L in the rpoB gene (RIF), S315T in the katG gene (INH), and C-15T in the inhA gene (INH) were most common (111, 80, and 31, respectively). The highest resistance to PZA was found when all three gene mutations were present in combination (20/23). Out of 24 PZA-resistant strains sequenced pncA gene mutation was found in 23 strains. Significantly high PZA resistance was detected in first-line resistant isolates, and this was much higher in combination mutations. The presence of these mutations predisposes the strain to acquisition of PZA resistance.

Indexed as

Antitubercular AgentsBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesMutationMycobacterium tuberculosisOxidoreductasesPyrazinamideAmidohydrolasesDrug Resistance, BacterialDrug Resistance, Multiple, BacterialHumansIsoniazidMicrobial Sensitivity TestsRifampinTuberculosis, Multidrug-ResistantAmidohydrolasesAntitubercular AgentsBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesInhA protein, MycobacteriumIsoniazidkatG protein, Mycobacterium tuberculosisOxidoreductasesPncA protein, Mycobacterium tuberculosisPyrazinamideRifampinrpoB protein, Mycobacterium tuberculosisIsoniazidLine probe assayMultidrug resistanceMycobacterium tuberculosisPyrazinamideRifampicin

Identifiers

PMID42151375

DOI10.1038/s41598-026-53296-8

PMCPMC13381933

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.